TY  - CHAP
A1  - Schwaneck, Stefan
A1  - Welge, Christopher
A1  - Bopp, Ann-Kathrin
A1  - Faulhaber, Sarah
A1  - Hampel, Susanne
A1  - Pfletschinger, Maike
A1  - Nebelung, Lisa
A1  - Hamme, Berit
A1  - Priddat, Birger
A1  - Salmen, Thomas
A1  - Rosenthal, Georg
A1  - Neumann, Bernd
A1  - Deeg, Steffen
A1  - Buytendijk, Frank
A1  - Gonzalez, Thomas
A1  - Träger, Gloria
A1  - Mayer, Benjamin
A1  - Mohamad, Christoph
A1  - Reinders, Heinz
A1  - Bohmeier, Bernhard
T1  - Chef, lass uns mal Kultur machen! Festschrift zum 6. Würzburger Wirtschaftssymposium
N2  - Am Montag, den 29. November 2010 fand das 6. Würzburger Wirtschaftssymposium unter dem Leitmotiv "Chef, lass uns mal Kultur machen!" statt. Die gemeinnützige Veranstaltung versteht sich seit jeher als Ort der Begegnung und des gemeinsamen Gedankenaustauschs, Studenten und Mitarbeiter aller Fachbereiche nahmen ebenso teil wie interessierte Bürger außerhalb der Würzburger Hochschulen. Die Festschrift enthält Interviews mit sowie Gastbeiträge von Referenten des 6. Würzburger Wirtschaftssymposiums. Darüber hinaus greifen Gastbeiträge von Experten aus Wissenschaft, Wirtschaft, Politik und Gesellschaft weitere Facetten auf und stellen das Thema damit auf eine breitere Grundlage.
KW  - Festschrift
KW  - Unternehmenskultur
KW  - Kulturwirtschaft
KW  - Geistiges Eigentum
KW  - Jugendkultur
KW  - Wirtschaft
KW  - Kultur
KW  - Unternehmenskultur
KW  - Kreativ- und Kulturwirtschaft
KW  - Mainfranken Theater
KW  - business culture
KW  - economics
KW  - intellectual property
Y1  - 2010
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-53329
SN  - 978-3-923959-66-2
ER  - 
TY  - JOUR
A1  - Lombardi, Jolina
A1  - Mayer, Benjamin
A1  - Semler, Elisa
A1  - Anderl‐Straub, Sarah
A1  - Uttner, Ingo
A1  - Kassubek, Jan
A1  - Diehl‐Schmid, Janine
A1  - Danek, Adrian
A1  - Levin, Johannes
A1  - Fassbender, Klaus
A1  - Fliessbach, Klaus
A1  - Schneider, Anja
A1  - Huppertz, Hans‐Jürgen
A1  - Jahn, Holger
A1  - Volk, Alexander
A1  - Kornhuber, Johannes
A1  - Landwehrmeyer, Bernhard
A1  - Lauer, Martin
A1  - Prudlo, Johannes
A1  - Wiltfang, Jens
A1  - Schroeter, Matthias L.
A1  - Ludolph, Albert
A1  - Otto, Markus
T1  - Quantifying progression in primary progressive aphasia with structural neuroimaging
JF  - Alzheimer's & Dementia
N2  - Introduction
The term primary progressive aphasia (PPA) sums up the non‐fluent (nfv), the semantic (sv), and the logopenic (lv) variant. Up to now, there is only limited data available concerning magnetic resonance imaging volumetry to monitor disease progression.
Methods
Structural brain imaging and an extensive assessment were applied at baseline and up to 4‐year(s) follow‐up in 269 participants. With automated atlas‐based volumetry 56 brain regions were assessed. Atrophy progression served to calculate sample sizes for therapeutic trials.
Results
At baseline highest atrophy appeared in parts of the left frontal lobe for nfvPPA (–17%) and of the left temporal lobe for svPPA (–34%) and lvPPA (–24%). Severest progression within 1‐year follow‐up occurred in the basal ganglia in nfvPPA (–7%), in the hippocampus/amygdala in svPPA (–9%), and in (medial) temporal regions in lvPPA (–6%).
Conclusion
PPA presents as a left‐dominant, mostly gray matter sensitive disease with considerable atrophy at baseline that proceeds variant‐specific.
KW  - atlas‐based volumetry
KW  - disease progression
KW  - frontotemporal dementia
KW  - longitudinal magnetic resonance imaging
KW  - primary progressive aphasia
KW  - sample size calculation
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-262605
VL  - 17
IS  - 10
SP  - 1595
EP  - 1609
ER  - 
TY  - JOUR
A1  - Rauch, Bernhard
A1  - Salzwedel, Annett
A1  - Bjarnason-Wehrens, Birna
A1  - Albus, Christian
A1  - Meng, Karin
A1  - Schmid, Jean-Paul
A1  - Benzer, Werner
A1  - Hackbusch, Matthes
A1  - Jensen, Katrin
A1  - Schwaab, Bernhard
A1  - Altenberger, Johann
A1  - Benjamin, Nicola
A1  - Bestehorn, Kurt
A1  - Bongarth, Christa
A1  - Dörr, Gesine
A1  - Eichler, Sarah
A1  - Einwang, Hans-Peter
A1  - Falk, Johannes
A1  - Glatz, Johannes
A1  - Gielen, Stephan
A1  - Grilli, Maurizio
A1  - Grünig, Ekkehard
A1  - Guha, Manju
A1  - Hermann, Matthias
A1  - Hoberg, Eike
A1  - Höfer, Stefan
A1  - Kaemmerer, Harald
A1  - Ladwig, Karl-Heinz
A1  - Mayer-Berger, Wolfgang
A1  - Metzendorf, Maria-Inti
A1  - Nebel, Roland
A1  - Neidenbach, Rhoia Clara
A1  - Niebauer, Josef
A1  - Nixdorff, Uwe
A1  - Oberhoffer, Renate
A1  - Reibis, Rona
A1  - Reiss, Nils
A1  - Saure, Daniel
A1  - Schlitt, Axel
A1  - Völler, Heinz
A1  - Känel, Roland von
A1  - Weinbrenner, Susanne
A1  - Westphal, Ronja
T1  - Cardiac rehabilitation in German speaking countries of Europe — evidence-based guidelines from Germany, Austria and Switzerland LLKardReha-DACH — Part 1
JF  - Journal of Clinical Medicine
N2  - Background: Although cardiovascular rehabilitation (CR) is well accepted in general, CR-attendance and delivery still considerably vary between the European countries. Moreover, clinical and prognostic effects of CR are not well established for a variety of cardiovascular diseases. Methods: The guidelines address all aspects of CR including indications, contents and delivery. By processing the guidelines, every step was externally supervised and moderated by independent members of the “Association of the Scientific Medical Societies in Germany” (AWMF). Four meta-analyses were performed to evaluate the prognostic effect of CR after acute coronary syndrome (ACS), after coronary bypass grafting (CABG), in patients with severe chronic systolic heart failure (HFrEF), and to define the effect of psychological interventions during CR. All other indications for CR-delivery were based on a predefined semi-structured literature search and recommendations were established by a formal consenting process including all medical societies involved in guideline generation. Results: Multidisciplinary CR is associated with a significant reduction in all-cause mortality in patients after ACS and after CABG, whereas HFrEF-patients (left ventricular ejection fraction <40%) especially benefit in terms of exercise capacity and health-related quality of life. Patients with other cardiovascular diseases also benefit from CR-participation, but the scientific evidence is less clear. There is increasing evidence that the beneficial effect of CR strongly depends on “treatment intensity” including medical supervision, treatment of cardiovascular risk factors, information and education, and a minimum of individually adapted exercise volume. Additional psychologic interventions should be performed on the basis of individual needs. Conclusions: These guidelines reinforce the substantial benefit of CR in specific clinical indications, but also describe remaining deficits in CR-delivery in clinical practice as well as in CR-science with respect to methodology and presentation.
KW  - cardiac rehabilitation standards
KW  - scientific guidelines
KW  - secondary prevention
KW  - coronary artery disease
KW  - chronic heart failure
KW  - heart valve repair
KW  - ICD-CRT
KW  - ventricular assist device
KW  - heart transplantation
KW  - peripheral artery disease
KW  - pulmonary hypertension
KW  - myocarditis
KW  - adults with congenital heart disease
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-239709
SN  - 2077-0383
VL  - 10
IS  - 10
ER  - 
TY  - JOUR
A1  - Huss, André
A1  - Abdelhak, Ahmed
A1  - Mayer, Benjamin
A1  - Tumani, Hayrettin
A1  - Müller, Hans-Peter
A1  - Althaus, Katharina
A1  - Kassubek, Jan
A1  - Otto, Markus
A1  - Ludolph, Albert C.
A1  - Yilmazer-Hanke, Deniz
A1  - Neugebauer, Hermann
T1  - Association of serum GFAP with functional and neurocognitive outcome in sporadic small vessel disease
JF  - Biomedicines
N2  - Cerebrospinal fluid (CSF) and serum biomarkers are critical for clinical decision making in neurological diseases. In cerebral small vessel disease (CSVD), white matter hyperintensities (WMH) are an important neuroimaging biomarker, but more blood-based biomarkers capturing different aspects of CSVD pathology are needed. In 42 sporadic CSVD patients, we prospectively analysed WMH on magnetic resonance imaging (MRI) and the biomarkers neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), chitinase3-like protein 1 (CHI3L1), Tau and Aβ1-42 in CSF and NfL and GFAP in serum. GFAP and CHI3L1 expression was studied in post-mortem brain tissue in additional cases. CSVD cases with higher serum NfL and GFAP levels had a higher modified Rankin Scale (mRS) and NIHSS score and lower CSF Aβ1-42 levels, whereas the CSF NfL and CHI3L1 levels were positively correlated with the WMH load. Moreover, the serum GFAP levels significantly correlated with the neurocognitive functions. Pathological analyses in CSVD revealed a high density of GFAP-immunoreactive fibrillary astrocytic processes in the periventricular white matter and clusters of CHI3L1-immunoreactive astrocytes in the basal ganglia and thalamus. Thus, besides NfL, serum GFAP is a highly promising fluid biomarker of sporadic CSVD, because it does not only correlate with the clinical severity but also correlates with the cognitive function in patients.
KW  - chitinase-3-like protein 1
KW  - GFAP
KW  - neurofilaments
KW  - white matter hyperintensities
KW  - biomarker
KW  - CSVD
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-285973
SN  - 2227-9059
VL  - 10
IS  - 8
ER  -